Sciclone Pharmaceuticals Inc
SCLN
SCLN was delisted on the 13th of October, 2017.
142 hedge funds and large institutions have $422M invested in Sciclone Pharmaceuticals Inc in 2017 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 56 increasing their positions, 39 reducing their positions, and 18 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 39
33% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 18
15% more capital invested
Capital invested by funds: $366M → $422M (+$55.6M)
4% more funds holding
Funds holding: 136 → 142 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
82% less call options, than puts
Call options by funds: $214K | Put options by funds: $1.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GP
GLG Partners
London,
United Kingdom
|
+$12.3M |
| 2 |
Two Sigma Investments
New York
|
+$6.99M |
| 3 |
Renaissance Technologies
New York
|
+$4.56M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$4M |
| 5 |
GH
GAM Holding
Zurich,
Switzerland
|
+$3.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$18.5M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$14.5M |
| 3 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$3.98M |
| 4 |
BlackRock
New York
|
-$2.45M |
| 5 |
SFM
Systematic Financial Management
Teaneck,
New Jersey
|
-$1.32M |
SCLN Hedge Fund Activity: Q2 2017 in Review
142 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q2 2017, worth a combined $422M — up 15% from $366M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new SCLN positions and 18 closed out — a net gain of 6 holders — while 56 added to existing stakes and 39 trimmed.
The largest buyer was GLG Partners, adding an estimated $12.3M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $18.5M sold.
- 142 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q2 2017, up from 136 in Q1 2017.
- Funds reported $422M of Sciclone Pharmaceuticals Inc stock for Q2 2017, up 15% quarter-over-quarter.
- 24 funds opened new Sciclone Pharmaceuticals Inc positions in Q2 2017 and 18 closed out, a net change of +6 holders.
- The largest Sciclone Pharmaceuticals Inc buyer in Q2 2017 was GLG Partners, an estimated $12.3M added.
- The largest Sciclone Pharmaceuticals Inc seller in Q2 2017 was Nantahala Capital Management, an estimated $18.5M sold.
Based on aggregated 13F filings for Q2 2017.